更昔洛韦注射液联合重组人干扰素α-1b治疗呼吸道合胞病毒肺炎患儿的疗效研究OA
Study on the effect of ganciclovir injection combined with recombinant human interferon α-1b in the treatment of RSV pneumonia in children
目的 探究呼吸道合胞病毒(respiratory syncytial virus,RSV)肺炎患儿经更昔洛韦注射液联合重组人干扰素α-1b治疗的疗效分析,为临床RSV肺炎患儿治疗方案的选择提供参考依据.方法 选取2021年12月至2023年12月在首都医科大学附属复兴医院确诊的105例RSV肺炎患儿(年龄3～8岁)为研究对象,采用随机数字表法将其分为联合组(35例)、对照组(35例)、常规组(35例).联合组给予更昔洛韦注射液联合重组人干扰素α-1b治疗,对照组给予重组人干扰素α-1b治疗,常规组接受常规治疗(如降温、祛痰、止咳、氧疗、基础抗病毒等).结果 联合组总有效率(94.29%,33/35)显著高于对照组(68.57%,24/35)和常规组(57.14%,20/35)(均P＜0.05).联合组咳嗽[(3.96±0.88)d]、喘鸣音[(3.39±0.85)d]、呼吸困难[(1.62±0.30)d]等临床症状缓解时长,均显著短于对照组[分别为(6.35±1.17)d,(5.57±1.12)d,(3.27±0.69)d]和常规组[分别为(7.59±1.34)d,(6.89±1.27)d,(4.62±0.84)d](均P＜0.05).治疗后,三组患儿肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、降钙素原(procalcitonin,PCT)、白介素(interleukin,IL)-10、CD8+T淋巴细胞、免疫球蛋白E(immunoglobulin E,IgE)水平均较治疗前降低,CD4+T淋巴细胞水平均较治疗前升高,且联合组上述指标的改善幅度更显著(均P＜0.05).结论 更昔洛韦注射液联合重组人干扰素α-1b能更好地改善RSV肺炎患儿的炎症反应以及临床症状,提高机体免疫功能,疗效确切且安全可靠.
Objective To investigate the therapeutic efficacy of ganciclovir injection combined with recombinant human interferon alpha-1b on children with respiratory syncytial virus(RSV)pneumonia,providing a basis for clinical diagnosis and treatment of RSV pneumonia.Method 105 pediatric patients with RSV pneumonia(admitted from December 2021 to December 2023,aged 3-8 years)were randomly separated into combination group(35 cases),control group(35 cases),and regular group(35 cases)in Fu Xing Hospital,Capital Medical University.The regular group received conventional treatment,the control group was treated with recombinant human interferon α-1b,and the combination group was treated with ganciclovir injection combined with recombinant human interferon α-1b(including antipyretic,expectorant,antitussive,oxygen therapy and basic antiviral therapy).Result The total effective rate of the combination group(94.29%,33/35)was higher than that of the control group(68.57%,24/35)and regular group(57.14%,20/35)(all P＜0.05).The improvement of clinical indicators such as cough[(3.96±0.88)d],wheezing[(3.39±0.85)d],and dyspnea[(1.62±0.30)d]in the combination group was better than that in the control group[(6.35±1.17)d,(5.57±1.12)d,(3.27±0.69)d,respectively]and regular group[(7.59±1.34)d,(6.89±1.27)d,(4.62±0.84)d,respectively](all P＜0.05).After treatment,the levels of tumor necrosis factor alpha(TNF-α),procalcitonin(PCT),interleukin(IL)-10,CD8+,and immunoglobulin E(IgE)in both groups of children decreased,while CD4+increased.And the improvement amplitude of the combination group was higher than that of the control group and regular group(all P＜0.05).Conclusion The combination of ganciclovir injection and recombinant human interferon α-1b can improve the clinical symptoms,reduce inflammatory response and improve immune function in children with RSV pneumonia,the efficacy is certain,with definite efficacy and good safety.
何耀红;谭言国;陈谨;屈爽
首都医科大学附属复兴医院呼吸科,北京 100038首都医科大学附属复兴医院呼吸科,北京 100038首都医科大学附属复兴医院呼吸科,北京 100038首都医科大学附属复兴医院呼吸科,北京 100038
医药卫生
呼吸道合胞病毒肺炎重组人干扰素α-1b更昔洛韦注射液疗效
Respiratory syncytial virus pneumoniaRecombinant human interferon α-1bGanciclovir injectionEfficacy
《新发传染病电子杂志》 2026 (2)
35-40,6
北京健康教育协会工作委托项目(BJK.JY202204)
评论